Apellis Pharmaceuticals ((APLS)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Apellis Pharmaceuticals is conducting a Phase 3 extension study titled A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration. The study aims to assess the long-term safety and effectiveness of pegcetacoplan in patients with geographic atrophy due to age-related macular degeneration, who previously participated in related studies.
The intervention being tested is pegcetacoplan (APL-2), a complement C3 inhibitor administered intravitreally. It is designed to slow the progression of geographic atrophy in affected patients.
The study employs a non-randomized, parallel intervention model with no masking, focusing on treatment as its primary purpose. Participants receive pegcetacoplan either monthly or every other month for up to 36 months.
The study began on March 4, 2021, with an estimated completion date in 2025. The latest update was submitted on June 23, 2025, indicating ongoing data collection and analysis.
This study update could influence Apellis Pharmaceuticals’ stock performance and investor sentiment, especially as the company competes in the age-related macular degeneration treatment market. Investors should watch for further developments and results.
The study is currently active and not recruiting, with more details available on the ClinicalTrials portal.